Press Releases

  • A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

  • VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test

  • VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

  • Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

  • Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

  • VolitionRx Appoints David Vanston as Chief Financial Officer

  • Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States

  • VolitionRx Limited Announces the Formation of Volition America, Inc.

  • VolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus